Compare · DFTX vs MNMD
DFTX vs MNMD
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Mind Medicine (MindMed) Inc. (MNMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and MNMD operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.92B, about 11.2x MNMD ($438.1M).
- Over the past year, DFTX is up 367.1% and MNMD is up 55.7% - DFTX leads by 311.5 points.
- DFTX has hit the wire 7 times in the past 4 weeks while MNMD has been quiet.
- MNMD has more recent analyst coverage (16 ratings vs 5 for DFTX).
PerformanceDFTX+158.94%MNMD+55.65%
2026-01-23+0.00%2026-07-21
- Company
- Definium Therapeutics Inc.
- Mind Medicine (MindMed) Inc.
- Price
- $45.03+5.23%
- $15.01+0.84%
- Market cap
- $4.92B
- $438.1M
- 1M return
- +84.21%
- +19.56%
- 1Y return
- +367.12%
- +55.65%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 7
- 0
- Recent ratings
- 5
- 16
MNMD
Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.
Latest DFTX
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Definium Therapeutics Announces New Employee Inducement Grants
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
- New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Definium Therapeutics Announces New Employee Inducement Grants
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Chief Legal Officer Sullivan Mark sold $585,750 worth of shares (13,008 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 320,571 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Karlin Daniel sold $451,876 worth of shares (10,035 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 503,282 units (SEC Form 4) (withholding obligation)
- Chief Financial Officer Roberts Brandi sold $135,675 worth of shares (3,013 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 209,487 units (SEC Form 4) (withholding obligation)
Latest MNMD
- Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Chief Legal Officer Sullivan Mark sold $148,244 worth of shares (11,276 units at $13.15), decreasing direct ownership by 4% to 282,576 units (SEC Form 4)
- Chief Executive Officer Barrow Robert sold $339,072 worth of shares (25,791 units at $13.15), decreasing direct ownership by 3% to 778,477 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel sold $73,623 worth of shares (5,600 units at $13.15), decreasing direct ownership by 1% to 425,025 units (SEC Form 4)
- SEC Form 144 filed by Mind Medicine (MindMed) Inc.
- MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
- MindMed Announces New Employee Inducement Grant
- MindMed Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Mind Medicine (MindMed) Inc.
- Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits